|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||187.56 - 193.04|
|52 Week Range||123.00 - 197.86|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||56.85|
|Earnings Date||Apr 22, 2019 - Apr 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||185.19|
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
High-margin stocks with 'pricing power' in their markets are well positioned for more gains ahead, according to Goldman Sachs. This group of 50 stocks has posted stunning performance in the past year compared to low-margin stocks, and may outperform in the upcoming period as rising costs continue to pressure U.S. corporations, says Goldman in its latest US Thematic Views report. "Growing margin pressures have driven the outperformance of stocks with high pricing power," the firm says.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
In addition, these stocks received very high ratings from GuruFocus for financial strength as well as profitability and growth. Warning! GuruFocus has detected 5 Warning Sign with EW. Edwards Lifesciences Corp. (EW) has gained 9% over the last week, 8% over the past month, 25% so far this year, 35% over the last 52 weeks and 122% over the past three years through March 18.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...
Edwards stock jumped to a record high Monday after the medtech company's TAVR heart-valve replacement outperformed surgery in a yearlong clinical study. Medtronic and Boston stocks sank.
The Fed's two-day policy meeting begins on Tuesday, where the central bank is widely expected to keep interest rates steady and reiterate its "patient" approach to monetary policy. Investors will be looking for whether the Fed's dot plot, which shows individual committee members' rate views for the coming three years, aligns with the patient approach.
gained more than 6% on Monday after the medical research and device company announced positive results related to its recent aortic valve surgical treatment trial. Edwards Lifesciences stock gained $10.91 to $190.66 on the New York Stock Exchange after the company on Saturday said its SAPIEN 3 transcatheter aortic valve proved successful in patient trials vs. more traditional open-heart surgery treatment.
Boeing shares slipped more than 1.5 percent after The Wall Street Journal reported that federal prosecutors and the Department of Transportation are scrutinizing the development of the company's 737 Max jets. An Ethiopian Airlines flight involving the 737 Max 8 crashed on March 10. Facebook FB — Shares of the social media giant fell more than 3 percent after an analyst at Needham downgraded them to hold from buy.
The S&P 500 and Nasdaq on Monday extended last week's gains, lifted by technology and financial stocks, as investors waited for the Federal Reserve's policy meeting later this week for further clues on the pace of interest rate hikes. At the central bank's two-day policy meeting which starts on Tuesday, the Fed is widely expected to stick to its pledge of a "patient" approach to monetary policy.
The S&P 500 and Nasdaq extended last week's gains on Monday, lifted by technology and financial stocks, as investors waited for the Federal Reserve's policy meeting later this week for further clues on the pace of interest rate hikes. The Dow was pressured by Boeing Co, which fell 2.7 percent after Ethiopia said an initial analysis of black boxes showed "clear similarities" in the March 10 plane crash with October's accident in Indonesia.
The Dow Jones industrials reversed from early losses to turn higher despite Boeing's renewed sell-off. Edwards Lifesciences stock jumped 8%.
China stocks and Edwards Lifesciences were early leaders Monday, helping stocks gain strength, even as Boeing weighed on the Dow Jones industrials.
A battle has broken out among doctors, hospitals and medical-device makers over whether an increasingly popular but risky medical procedure for replacing defective heart valves should be offered more widely. The fight is over which hospitals can get paid by the federal government to perform the procedure, often referred to as TAVR, for transcatheter aortic valve replacement. Currently, bigger hospitals that perform the procedures more frequently are favored under federal reimbursement policies—based on studies linking volume to quality—while smaller hospitals have a tougher time meeting the rules to start or maintain TAVR offerings.
The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year. The results of the trial will be presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, and have been published online in the New England Journal of Medicine.
Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday. Both companies already have approvals for their TAVR (transcatheter aortic valve replacement) systems for use in patients too frail to endure surgery and those deemed at intermediate risk. An estimated 165,000 low-risk patients suffer from severe aortic stenosis each year in the United States, Western Europe and Japan, a condition that can lead to heart failure in as little as two years, Medtronic said.
The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.
Edwards Lifesciences Corp NYSE:EWView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EW had net inflows of $3.54 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 03/08/2019 at an average price of $167.89 a share.
Looking at Edwards Lifesciences Corporation's (NYSE:EW) earnings update on 31 December 2018, it seems that analyst forecasts are substantially optimistic, as a 52% rise in profits is expected in theRead More...